Little is known of the course of COVID-19 and the antibody response to infection or vaccination in patients with hairy-cell leukaemia (HCL). Among a total of 58 HCL cases we studied in these regards, 37 unvaccinated patients, mostly enjoying a relatively long period free from anti-leukaemic treatment, developed COVID-19 between March 2020 and December 2021 with a usually favourable outcome (fatality rate: 5/37, 14%); however, active leukaemia, older age and more comorbidities were associated with a worse course. Postinfection (n = 11 cases) and postvaccination (n = 28) seroconversion consistently developed, except after recent anti-CD20 or venetoclax therapy, correlating with perivaccine B-cell count. Vaccination appeared to protect from severe COVID-19 in 11 patients with breakthrough infection.
SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia / Tiacci, E; Mancini, A; Marchetti, M; D'Elia, Gm; Candoni, A; Morotti, A; Romano, A; Gozzetti, A; Broccoli, A; De Carolis, L; Bruna, R; Tisi, Mc; Selleri, C; Capponi, M; Vallisa, D; Cattaneo, C; Della Porta, Mg; Busca, A; Falini, B; Massaia, M; Bertu, L; Pulsoni, A; Rivela, P; Corradini, P; Passamonti, F. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - (2022). [10.1111/bjh.18606]
SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia
Pulsoni, A;
2022
Abstract
Little is known of the course of COVID-19 and the antibody response to infection or vaccination in patients with hairy-cell leukaemia (HCL). Among a total of 58 HCL cases we studied in these regards, 37 unvaccinated patients, mostly enjoying a relatively long period free from anti-leukaemic treatment, developed COVID-19 between March 2020 and December 2021 with a usually favourable outcome (fatality rate: 5/37, 14%); however, active leukaemia, older age and more comorbidities were associated with a worse course. Postinfection (n = 11 cases) and postvaccination (n = 28) seroconversion consistently developed, except after recent anti-CD20 or venetoclax therapy, correlating with perivaccine B-cell count. Vaccination appeared to protect from severe COVID-19 in 11 patients with breakthrough infection.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
